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Summary
 
In this study, by the generation of a specific monoclonal antibody, we identified p75/AIRM1
(for adhesion inhibitory receptor molecule 1), a novel inhibitory receptor that is mostly con-
fined to human natural killer cells. p75/AIRM1 is a 75-kD glycoprotein that, upon sodium
pervanadate treatment, becomes tyrosine phosphorylated and associates to src homology 2 do-
main–bearing protein tyrosine phosphatase (SHP)-1. The p75/AIRM1 gene is located on hu-
man chromosome 19 and encodes a novel member of the sialoadhesin family characterized
by three immunoglobulin-like extracellular domains (one NH
 
2
 
-terminal V-type and two C2-
type) and a classical immunoreceptor tyrosine–based inhibitory motif (ITIM) in the cytoplas-
mic portion. The highest amino acid sequence similarity has been found with the myeloid-
specific CD33 molecule and the placental CD33L1 protein. Similar to other sialoadhesin
molecules, p75/AIRM1 appears to mediate sialic acid–dependent ligand recognition.
Key words: molecular cloning • natural killer cells • sialoadhesin • inhibitory receptor • 
immunoglobulin superfamily
 
R
 
elevant progress has been made in recent years to-
wards a better understanding of the molecular inter-
actions responsible for the regulation of NK cell functions.
In particular, the finding that NK cells are capable of killing
target cells lacking MHC class I proteins on their surface (1)
has been the basis for the identification of a series of inhibi-
tory receptors present on NK cells that bind MHC mole-
cules expressed on target cells. In humans, these receptors
are expressed on subsets of NK cells and recognize either
discrete HLA class I alleles or nonclassical HLA class I mol-
ecules (1–3). The first group includes members of the im-
munoglobulin superfamily (Ig-SF)
 
1
 
 that are referred to as
killer inhibitory receptors (KIRs). KIRs are characterized
by the ability to specifically recognize distinct groups of
HLA-A (4), -B (5), or -C (6) alleles. The second group is
represented by members of the C-type lectin superfamily
that covalently associate to form the CD94/NKG2 recep-
tors (7–9); the inhibitory CD94/NKG2A receptor has
been shown to be specific for the nonclassical HLA class I
molecule, HLA-E (3, 10). More recently, several additional
inhibitory receptors, either HLA class I specific or not,
have been identified that may exert a regulatory activity on
human NK cell function; these include, for example, the
leukocyte Ig-like receptor 1/Ig-like transcript 2 (LIR-1/
ILT-2 [11, 12]) and the p40/leukocyte-associated Ig-like
receptor 1 (LAIR-1) (13, 14) molecules. All of the inhibi-
tory receptors identified so far are characterized by one or
more immunoreceptor tyrosine–based inhibitory motifs
(ITIMs) in their cytoplasmic tail. Upon tyrosine phosphor-
ylation, ITIM binds the src homology (SH)2 domains of
phosphatases such as SHP-1 and SHP-2 that, in turn, cause
downregulation of NK cell triggering and cytotoxicity (15).
In an attempt to identify novel receptors possibly in-
volved in the negative regulation of NK cell function, we
immunized mice with human NK cell clones and screened
for mAbs capable of modulating the NK-mediated cytoly-
sis. Using this approach, we selected an mAb (Z176) spe-
cific for a novel inhibitory surface molecule of 
 
z
 
75 kD
(p75) termed adhesion inhibitory receptor molecule 1
(AIRM1). p75/AIRM1 is expressed on the majority of hu-
man NK cells. Molecular cloning revealed a novel member
of the Ig-SF characterized by three Ig-like domains in the
extracellular portion and an ITIM in the cytoplasmic tail.
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); AIRM1, adhesion inhib-
itory receptor molecule 1; Ig-SF, immunoglobulin superfamily; ILT, Ig-
like transcript; ITIM, immunoreceptor tyrosine–based inhibitory motif;
KIR, killer inhibitory receptor; LIR, leukocyte Ig-like receptor; MAG,
myelin-associated glycoprotein; RT, reverse transcriptase; SH, src homol-
ogy domain; SHP, SH2 domain–bearing protein tyrosine phosphatase. 
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Although p75/ARM1 does not recognize HLA class I
molecules, its amino acid (aa) sequence, together with
functional data, suggests that it represents a novel member
of the sialoadhesin family. In conclusion, p75/AIRM1 is a
novel, HLA-independent, inhibitory receptor that may
play a relevant role in the negative regulation of human
NK cell functions.
 
Materials and Methods
 
mAbs.
 
Z176 (IgG2b) mAb was obtained by immunizing a
5-wk-old BALB/c mouse with the NK clone SA260 (surface
phenotype: CD3
 
2
 
CD16
 
1
 
, CD56
 
1
 
, NKp46
 
1
 
, NKp44
 
1
 
, p70/
NKB1
 
1
 
, CD94/NKG2A
 
1
 
) as described previously (16). The fol-
lowing mAbs were produced in our laboratory: JT3A (IgG2a,
anti-CD3), BAB281 (IgG1, anti-NKp46), Z231 and KS38 (IgG1
and IgM, respectively, anti-NKp44), Z199 (IgG2b, anti-
NKG2A), Z27 (IgG1, anti-p70/NKB1), KD1 and c127 (IgG2a
and IgG1, respectively, anti-CD16), and c218 and A6-90 (IgG1
and IgG2b, respectively, anti-CD56). The MCA531 mAb (IgM,
anti-CD20) was purchased from Serotec. The D1.12 mAb
(IgG2a, anti–HLA-DR) was provided by Dr. R.S. Accolla (Uni-
versità di Pavia, Pavia, Italy). The HP2.6 mAb (IgG2a, anti-CD4)
was provided by Dr. P. Sanchez-Madrid (Hospital de la Princesa,
Madrid, Spain).
 
Purification of Polyclonal or Clonal NK and T Cell Populations.
 
To obtain PBLs, PBMCs derived from healthy donors were iso-
lated on Ficoll-Hypaque gradients and depleted of plastic-adher-
ent cells. PBLs were either used directly or were incubated
with anti-CD3 (JT3A), anti-CD4 (HP2.6), and anti–HLA-DR
(D1.12) mAbs for 30 min at 4
 
8
 
C, followed by immunomagnetic
depletion with goat anti–mouse coated Dynabeads (Dynal; 30
min, 4
 
8
 
C; reference 17). NK or T cell clones were obtained by
limiting dilution in the presence of irradiated feeder cells, 1.5 ng/ml
PHA (GIBCO BRL), and 100 U/ml rIL-2 (Proleukin; Chiron
Corp.) as described previously (18).
 
Cytolytic Activity and Flow Cytofluorimetric Analysis.
 
NK cell
clones were tested for cytolytic activity against the Fc
 
g
 
R
 
1
 
 P815
murine mastocytoma cell line in a 4-h 
 
51
 
Cr-release assay as de-
scribed previously (2). The E/T ratio used was 8:1 in all instances.
For one- or two-color cytofluorimetric analysis (FACScan™;
Becton Dickinson), cells were stained with the appropriate mAbs
followed by PE- or FITC-conjugated isotype-specific goat anti–
mouse second reagent (Southern Biotechnology Associates) (17).
 
Biochemical Characterization of the p75/AIRM1 Molecules.
 
Seph-
arose-protein A–coupled Z176 and Z199 mAbs or cyanogen
bromide Sepharose (Amersham Pharmacia Biotech)-coupled Z27
mAb were used to immunoprecipitate specific molecules from
1% NP-40 lysates of cells surface labeled with 
 
125
 
I (NEN) as de-
scribed previously (19). Immunoprecipitates were analyzed by
discontinuous SDS-PAGE either undigested or digested with
 
N
 
-glycosidase F or 
 
O
 
-glycosidase (Boehringer Mannheim)
 
 
 
(20).
For two-dimensional peptide mapping (2DPM) analysis, the
purified proteins were digested with pepsin, and peptides were
analyzed by electrophoresis in the first dimension (Multiphor II;
Amersham Pharmacia Biotech) followed by chromatography in
the second dimension (20). NK cells (10
 
8
 
) were stimulated or not
with 100 
 
m
 
M sodium pervanadate (19), and 1% NP-40 lysates
were immunoprecipitated with the Z176 mAb. Samples were an-
alyzed in discontinuous SDS-PAGE, transferred to Immobilon
 
 P
 
(Millipore Corp.), and then probed with antiphosphotyrosine
mAb (PY20-HRPO; Transduction Laboratories) or anti–SHP-1
and SHP-2 phosphatases (PTP1C and PTP1D, respectively;
Transduction Laboratories). The Renaissance Chemilumines-
cence kit (NEN) was used for detection.
 
cDNA Library and Screening.
 
cDNA was synthesized from
RNA prepared from two IL-2–activated polyclonal NK cells and
inserted in the expression vector VR1012. The cDNA library,
fractionated in 10 pools of 200,000 different inserts, was trans-
fected into COS-7 cells by DEAE-dextran method and immuno-
cytochemical staining using the Z176-specific mAb and sib selec-
tion (21).
 
DNA Sequencing.
 
DNA sequencing was performed using
d-Rhodamine Terminator Cycle Sequencing kit and a 377 ABI
automatic sequencer (Perkin Elmer-Applied Biosystems).
 
Adhesion Assay.
 
COS-7 cells were transfected with VR1012–
AIRM1 construct by DEAE-dextran method (4). After 48 h,
cells were trypsinized and analyzed by immunofluorescence stain-
ing for the expression of p75/AIRM1 molecules. Transfected
cells and human RBCs were washed twice with serum-free
DMEM. The COS-7 cell/RBC ratio used in the experiments
was 1:20; the adhesion assay was performed for 30 min at 4
 
8
 
C.
The binding of RBCs to COS-7 cells was quantified by counting
the percentage of COS-7 cells that bound more than seven
erythrocytes. Neuraminidase treatment was carried out by incu-
bating RBCs with 0.1 U/ml of Vibrio cholera neuraminidase
(Behringwerke AG) for 3 h at 37
 
8
 
C followed by two washes with
DMEM. For cellular adhesion blocking experiments, 10
 
6
 
AIRM1-transfected COS-7 cells were incubated with 0.5 ml
Z176 mAb supernatant for 30 min at 4
 
8
 
C followed by two
washes with DMEM before the adhesion assay.
 
Chromosomal Localization and Zoo-Blot™.
 
The Somatic Cell Hy-
brid blot (BIOS Laboratories), containing 20 multi-chromosomal
somatic human/hamster cell hybrids plus 3 control genomic
DNAs (human, hamster, and mouse) digested with EcoRI, was
used to assign the AIRM1 gene to a specific chromosome. A
1203-bp cDNA probe, obtained digesting VR1012–AIRM1 con-
struct with SalI and PstI restriction enzymes, was used to perform
high stringency hybridization (22). Analysis of cross-specific con-
servation of AIRM1 gene was performed using Zoo-Blot™ from
Clontech. This Southern blot contained genomic DNA from hu-
mans, Rhesus monkey, Sprague-Dawley rat, BALB/c mouse,
dog, cow, rabbit, chicken, and 
 
Saccharomyces cerevisiae
 
 yeast. Washes
were carried out under low stringency conditions (23).
 
Reverse Transcriptase PCR Amplification of AIRM1 cDNA.
 
RNA extracted using RNAzol (Cinna/Biotecx) and oligo (dT)–
primed cDNA was prepared from polyclonal NK cell populations
and clones by standard techniques. The set of primers AIRM1-up
(containing the ATG initiation codon; 5
 
9
 
 TCC AAC CCC AGA
TAT GCT G) and AIRM1-down (designed in the 3
 
9
 
 untrans-
lated region; 5
 
9
 
 ACA AGC CCG AGC CTC TGC) were used
to amplify the AIRM1 open reading frame. 30 cycles of PCR (30 s
at 95
 
8
 
C, 30 s at 60
 
8
 
C, and 30 s at 72
 
8
 
C) were performed using
TAQ-GOLD (Perkin Elmer-Applied Biosystems) after a preacti-
vation of 15 min at 95
 
8
 
C. The amplification products obtained
from polyclonal NK cells populations were purified from gel,
subcloned into pcDNA3.1/V5/His TOPO™ vector using the
Eukaryotic TOPO TA Cloning
 
®
 
 kit (Invitrogen), and sequenced.
 
Results
 
Identification and Cellular Distribution of a Novel NK Cell
Surface Molecule with Inhibitory Function.
 
Mice were immu-
nized with the NK cell clone SA260 (surface phenotype: 
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CD3
 
2
 
CD16
 
1
 
, CD56
 
1
 
, NKp46
 
1
 
, NKp44
 
1
 
, p70/NKB1
 
1
 
,
CD94/NKG2A
 
1
 
), characterized by a strong cytolytic ac-
tivity against the P815 murine mastocytoma cell line. After
cell fusion, mAbs were analyzed for their ability to inhibit
the cytotoxicity mediated by NK cell clones in a classical
redirected killing assay against the Fc
 
g
 
R
 
1
 
 P815 cell line.
By using this screening procedure, we isolated the Z176
mAb (IgG2b) that inhibited the cytolytic activity of the
majority of the NK cell clones analyzed. Fig. 1 shows four
representatives of such clones, including the immunizing
SA260 clone. In three of these clones, the addition of Z176
mAb (but not of an isotype-matched anti-CD56 mAb) re-
sulted in inhibition of the spontaneous cytolytic activity
against P815 cells (Fig. 1 a). Clone D414 is representative
of the infrequent NK cell clones in which no inhibitory ef-
fect could be detected. Immunofluorescence and FACS
 
®
 
analysis of the same clones (Fig. 1 b) revealed that Z176
mAb reacted with clones SA260, LM15, and LM8 but not
with clone D414. Similar data were obtained in a large
panel of NK cell clones, thus suggesting that the Z176
mAb–reactive molecule is expressed and delivers inhibitory
signal in the majority of, but not all, human NK cells.
We next analyzed the cell surface distribution of the
Z176 mAb–reacting molecule in PBLs by two-color im-
munofluorescence and FACS
 
®
 
 analysis. As shown in Fig. 2,
all CD56
 
1
 
 cells were stained by the Z176 mAb. In con-
trast, Z176 mAb did not stain CD3
 
1
 
 T cells or CD20
 
1
 
 B
cells. Only in some individuals was a minor fraction (
 
,
 
5%)
of T cells found to be Z176
 
1
 
 (see donor B). Although not
shown, further analysis of the Z176 surface expression in
NK cell–enriched fractions of PBLs (upon depletion of
CD3
 
1
 
HLA-DR
 
1
 
 cells) confirmed that most NK cells re-
acted with Z176 mAb while Z176
 
2
 
 NK cells were rather
infrequent. Analysis of a large panel (
 
.
 
100) of T cell clones
(both 
 
a
 
/
 
b
 
1
 
 and 
 
g
 
/
 
d
 
1
 
) showed that Z176-reactive mole-
cules are not expressed by T lymphocytes after cell activa-
tion or clonal expansion (not shown). Finally, Z176 mAb
did not stain EBV-transformed B cell lines (including Raji,
Daudi, and C1R) or T cell lines (such as JA3, HSB-2,
CEM, MOLT-4, H9, and Jurkat). Remarkably, it also
failed to stain NK cell lines, including NK3.3, NKL, and
YT (not shown).
 
Biochemical Characterization of the Surface Molecule Recog-
nized by Z176 mAb.
 
A polyclonal NK cell population
was surface labeled with 
 
125
 
I and immunoprecipitated with
Z176 mAb. This antibody immunoprecipitated a molecule
with a molecular mass of 
 
z
 
75 kD (p75) both under nonre-
ducing (not shown) and reducing conditions (Fig. 3 a). To
analyze their glycosylation pattern, p75 molecules were
treated with different enzymes. The molecular mass was
Figure 1. Surface expression of Z176-reactive mole-
cules in representative human NK cell clones and the
inhibitory effect of Z176 on the NK-mediated cyto-
toxicity. (a) Four representative NK cell clones were
analyzed in a redirected killing assay against the
FcgR1 P815 target cell line either in the absence
(white bars) or presence of Z176 (black bars), c127
(anti-CD16, striped bars), or A6-90 (anti-CD56, stip-
pled bars) mAb. (b) The NK cell clones were analyzed
by immunofluorescence and FACS® analysis for the ex-
pression of Z176-reactive surface molecules. Cells were
stained with Z176 mAb followed by PE-conjugated
isotype-specific goat anti–mouse second reagent. Open
profiles represent cells stained with the second reagent
alone. a.u., arbitrary units. 
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not modified by treatment with 
 
O
 
-glycosidase (not shown).
In contrast, digestion with 
 
N
 
-glycosidase revealed a protein
backbone of 
 
z
 
48 kD (Fig. 3 a), thus suggesting a relatively
high 
 
N
 
-glycosylation pattern. Finally, in two-dimensional
peptide mapping (2DPM) analysis, p75 displayed a diges-
tion pattern that was different from those of known inhibi-
tory receptors, including p70/NKB1 and NKG2A (not
shown). Altogether, these data support the notion that p75
is a novel surface molecule with inhibitory function ex-
pressed by the majority of human NK cells.
 
It is well known that inhibitory receptors, including p58
(CD158), p70/NKB1, CD94/NKG2A, and LIR-1/ILT-2,
are characterized by the presence of ITIM sequences in
their cytoplasmic tail. ITIMs, upon tyrosine phosphoryla-
tion, recruit SH2-containing phosphatases such as SHP-1
and SHP-2. To assess whether the p75 molecule could also
belong to the ITIM-bearing receptor family, a polyclonal
NK cell population, treated or not with sodium pervana-
date, was immunoprecipitated with Z176 mAb. Samples
were probed with antiphosphotyrosine, anti–SHP-1, or
anti–SHP-2 mAbs. Fig. 3 b shows that treatment with so-
dium pervanadate leads to p75 tyrosine phosphorylation
(left panel) and association with SHP-1 (right panel). It is of
note that, under the same conditions, no association with
SHP-2 could be detected (not shown). These data strongly
suggest that p75 contains at least one typical ITIM in the
cytoplasmic tail.
 
Molecular Cloning and Characterization of the cDNA En-
coding the p75 Molecule.
 
A cDNA library, prepared from
RNA derived from 2 polyclonal NK cell populations, frac-
tionated in 10 different pools, was transiently transfected
into COS-7 cells. After 48 h, cells were tested for reactivity
with Z176 mAb by immunocytochemical staining. The
plasmidic DNA of the positive pool was amplified in
 
Escherichia coli
 
, fractionated
 
 
 
in smaller subpools, and trans-
fected into COS-7 cells. Six rounds of transfections and
screening allowed the isolation of an individual cDNA
termed AIRM1.
As shown in Fig. 4 a, COS-7 cells transfected with
VR1012–AIRM1 construct were brightly stained with
Z176 mAb in cytofluorimetric analysis. Cell transfectants
were then surface labeled with 
 
125
 
I, and cell lysates were
immunoprecipitated with Z176 mAb. As shown in Fig. 4 b,
the immunoprecipitated molecule displayed a molecular
mass slightly lower than that immunoprecipitated from NK
cells. This difference in molecular mass could reflect a non-
Figure 2. Expression of Z176-
reactive molecules in PBL sub-
sets. Freshly isolated PBLs were
analyzed by two-color immuno-
fluorescence and FACS® analysis
for the expression of Z176-reac-
tive molecules in combination
with CD3, CD56, or CD20
surface molecules. Cells were
stained with Z176, JT3A (anti-
CD3), c218 (anti-CD56), and
MCA531 (anti-CD20) mAbs
followed by PE- or FITC-con-
jugated isotype-specific goat
anti–mouse second reagent. The
contour plots were divided
into  quadrants representing un-
stained cells (bottom left), cells
with only red fluorescence (top
left), cells with red and green flu-
orescence (top right), and cells
with only green fluorescence
(bottom right).
Figure 3. Biochemical analysis of Z176-reactive molecules and their
association with SHP-1 phosphatase. (a) A polyclonal NK population was
surface labeled with 125I and immunoprecipitated with anti-NKG2A
(Z199 mAb, lanes A and B), anti-p70/NKB-1 (Z27 mAb, lanes C and
D), and Z176 mAb (lanes E and F). Samples were analyzed in an 8%
SDS-PAGE under reducing conditions either undigested (2) or digested
(1) with N-glycosidase. Molecular weight markers (in kD) are indicated
on the right. (b) 1% NP-40 cell lysates derived from a polyclonal NK cell
population, untreated (2) or treated (1) with sodium pervanadate, were
immunoprecipitated with Z176 mAb. Samples were analyzed in an 11%
SDS-PAGE under reducing conditions, transferred to polyvinylidene di-
fluoride membranes, and probed with either antiphosphotyrosine (anti-
PTyr) or anti–SHP-1 mAb. 
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complete 
 
N
 
-glycosylation in COS-7 cell transfectants. In-
deed, upon treatment with 
 
N
 
-glycosidase, the molecule
immunoprecipitated from AIRM1 transfectants displayed a
48-kD protein backbone identical to that of the p75 mole-
cule isolated from NK cells.
Fig. 5 shows the nucleotide sequence (1766 bp) of
AIRM1 and its predicted amino acid translation (467 aa).
The 5
 
9
 
 noncoding region consists of 64 nucleotides, and in
the 3
 
9
 
 noncoding sequence a possible polyadenylation sig-
nal (AAUAUA) preceded the poly A tail. The putative
protein appears as a type I transmembrane molecule be-
longing to the Ig-SF. An 18 aa leader peptide precedes a
335 aa extracellular portion characterized by an NH
 
2
 
-ter-
minal V-type domain followed by two C2-type domains.
Six putative O-glycosylation sites and eight putative N-gly-
cosylation sites are present in the extracellular portion. The
predicted polypeptide mass is z48 kD, thus corresponding
to the protein backbone of the p75 molecule immunopre-
cipitated by Z176 mAb from both NK cells and p75/
AIRM1 COS-7 transfectants.
The 23 aa hydrophobic transmembrane portion is fol-
lowed by a cytoplasmic tail (91 aa) containing two tyrosine
residues. Remarkably, Tyr 437 is part of a typical ITIM
motif (435–440 5 IQYAPL). Finally, other consensus se-
quences for putative phosphorylation sites are present in
the cytoplasmic tail: a 39–59 adenosine monophosphate
(cAMP)-dependent protein kinase phosphorylation site,
three protein kinase phosphorylation sites, and five casein
kinase 2 (CK2) phosphorylation sites.
Comparison of the aa sequence of p75/AIRM1 with
those of known proteins in the EMBL/GenBank/DDBJ
database revealed significant similarity with the placenta an-
tigen CD33L1 (24), as well as with the myeloid lineage
molecule CD33 (25) (Fig. 6). In particular, both the IgV
domain and the transmembrane region of p75/AIRM1 dis-
play a high degree of aa identity (55 and 61%, respectively)
with CD33 molecule. On the other hand, the IgC2a and
IgC2b domains display a remarkable similarity with those
of CD33L1. In this context, the highest degree of aa iden-
tity (73%) was found between the IgC2a domain of p75/
AIRM1 and that of CD33L1. The IgV and IgC2a domains
of p75/AIRM1 contain two Cys residues at position 41
and 174. Cys residues located at the same relative positions
are also present in different sialoadhesins (26, 27) and are
likely to be involved in the formation of interdomain
bridges. Altogether, these results suggest that the p75/
AIRM1 molecule may represent a novel member of the
sialoadhesin family.
To identify the human chromosome carrying the p75/
AIRM1-encoding gene, genomic DNA samples derived
from a panel of human/hamster somatic cell hybrids were
Figure 4. Surface expression and biochemical analysis of Z176-reactive
molecules in COS-7 cells transfected with VR1012–AIRM1 construct.
(a) AIRM1-transfected COS-7 cells were analyzed for surface expression
using Z176 mAb followed by PE-conjugated isotype-specific goat anti–
mouse second reagent. The open profile represents cells stained with the
second reagent alone. (b) A polyclonal NK cell population (lanes A and
B) and AIRM1-transfected COS-7 cells (lanes C and D) were surface la-
beled with 125I and immunoprecipitated with Z176 mAb. Samples were
analyzed in an 8% SDS-PAGE under reducing conditions either undi-
gested (2) or digested (1) with N-glycosidase. Molecular weight markers
(in kD) are indicated on the right.
Figure 5. AIRM1 cDNA nucleotide sequence and its predicted aa
translation. aa included in the signal peptide are indicated in small letters.
Cysteine residues are circled. The predicted transmembrane portion is
underlined. Potential N- and O-glycosylation sites are boxed. The ITIM
sequence is double underlined. The AIRM1 nucleotide sequence is avail-
able from EMBL/GenBank/DDBJ under accession no. AJ007395.798 Cloning of a Novel Sialoadhesin Member Expressed by NK Cells
analyzed with a 1203-bp AIRM1-specific probe. We could
localize the AIRM1 gene on human chromosome 19, since
only the somatic cell hybrids containing this chromosome
were positive in Southern blot analysis (Fig. 7). Moreover,
the simple pattern of hybridization observed suggests that
AIRM1 is a single gene or a few copy genes. It is of note
that other members of the sialoadhesin family, including
CD33 (28) and CD33L1 (24), myelin-associated glycopro-
tein (MAG [29]), CD22 (30), and Siglec-5 (31), have been
mapped on human chromosome 19.
Reverse transcriptase (RT)-PCR analysis was performed
on polyclonal NK cell populations and clones, derived from
five different donors. Using the set of primers AIRM1-up
and AIRM1-down, we could detect, not only in poly-
clonal populations but also in NK cell clones, three ampli-
fied products of z1.4, 1.1, and 0.7 kb, respectively (not
shown). These cDNA fragments were subcloned and se-
quenced. The 1.4-kb product was found to correspond to
the AIRM1 cloned cDNA. Moreover, the sequence analy-
sis, performed in five different donors, revealed only an al-
lelic variant of AIRM1 cDNA (termed AIRM1b; sequence
data available from EMBL under accession no. AJ130710)
characterized by two silent substitutions (codon 105, ACC
instead of AAT; and codon 452, GGT instead of GGA).
Binding of AIRM1-transfected COS-7 Cells to RBCs.
Different members of the sialoadhesin family, including
CD22 (32, 33) and Sialoadhesin (34, 35), have been shown
to mediate sialic acid–dependent binding to RBCs. As
shown in Fig. 8, COS-7 cells transfected with the AIRM1
cDNA efficiently bound to RBCs. AIRM1-specific rosette
formation occurred both at 48C (Fig. 8) and at 378C (not
shown). Pretreatment of RBCs with neuraminidase abro-
gated their binding to AIRM1 transfectants, suggesting that
adhesion occurs through a sialic acid–dependent mecha-
nism. In addition, binding to RBCs was inhibited when
AIRM1 transfectants were preincubated with Z176 mAb
(but not with an isotype-matched mAb), thus indicating a
direct involvement of p75/AIRM1 in the RBC–AIRM1
transfectant interaction.
Discussion
In this study, we describe a novel inhibitory receptor,
termed p75/AIRM1, which is expressed by resting and ac-
tivated human NK cells and may play a role in the regula-
tion of their function. Molecular and functional analysis re-
vealed a novel member of the sialoadhesin family; thus,
p75/AIRM1 differs from the other major inhibitory recep-
tors expressed by NK cells that are characterized by their
specificity for MHC class I molecules.
p75/AIRM1 is a transmembrane glycoprotein character-
ized by one IgV and two IgC2-type Ig-like domains in the
extracellular portion that displays similarity with members
of the sialoadhesin family. This family is composed of struc-
turally and functionally related molecules, including MAG,
Schwann cell myelin protein (SMP), Sialoadhesin, CD22,
CD33, CD33L1, and Siglec-5. All of these proteins are
characterized by a restricted cell expression pattern. In par-
ticular, MAG (36) and Schwann cell myelin protein (SMP)
(37) are found in the nervous system on oligodendroglia
and Schwann cells, respectively; CD22 is expressed on a
subset of B lymphocytes (38), sialoadhesin on a subset of
macrophages (39), CD33 (40) and Siglec-5 (31) on cells of
the myelomonocytic lineage, and CD33L1 in placenta
(24). Similar to these molecules, p75/AIRM1 also displays
a restricted cell expression pattern, being essentially con-
fined to NK cells. Other than their ability to bind sialic
acid, limited information is available on the function of the
molecules of the sialoadhesin family. The only molecule
reported to display inhibitory function (i.e., similar to p75/
AIRM1) is CD22 that is expressed on B cells, in which it
may downregulate the B cell receptor–mediated cell trig-
gering. CD33 is selectively expressed by hemopoietic cells,
in which it represents an important marker in normal dif-
Figure 6. aa alignment of p75/AIRM1, human CD33, and CD33L1 molecules. The conserved cysteines involved in the interdomain bridges and the
conserved tyrosines are indicated by black and white arrows, respectively. Dashes indicate gaps inserted to optimize alignments. Dots indicate identical aa.799 Falco et al.
ferentiation as well as in leukemia typing. In view of the
similarity with p75/AIRM1, which includes the presence
of an ITIM sequence in the cytoplasmic tail, it is important
to reinvestigate the role of CD33, especially with respect to
its possible inhibitory effect on hemopoietic cell function
and/or differentiation. Experiments along this line are in
progress in our laboratory.
p75/AIRM1 is encoded by a gene localized on hu-
man chromosome 19. Remarkably, genes coding for other
members of the sialoadhesin family map on chromosome
19 as well. This may suggest that all of these molecules,
including p75/AIRM1, may have evolved through dupli-
cation of a common ancestral gene. It is of note that other
inhibitory receptors involved in the regulation of NK-
mediated cytotoxicity, including KIRs, LIR/ILT, and
LAIR-1, have also been mapped on this chromosome. Al-
though not shown, the AIRM1-specific probe, under low
stringency conditions, hybridized with genomic DNA
from Rhesus monkey, thus suggesting a cross-species con-
servation between humans and monkeys.
DNA sequencing of seven cDNA clones obtained by
RT-PCR experiments, performed in five different donors,
revealed only an allelic variant characterized by two silent
substitutions. However, considering both the relatively low
number of samples analyzed and the fact that all donors be-
longed to the Caucasoid race, a polymorphism of the p75/
AIRM1 gene cannot be ruled out. RT-PCR analysis, in
addition to the 1.4-kb AIRM1 transcript, also allowed the
identification of two alternatively spliced products of 1.1
and 0.7 kb, respectively. Sequence of these products re-
vealed that the 1.1-kb fragment encoded a putative protein
identical to the p75/AIRM1 but lacking the IgC2a domain
(from codon 146 to codon 238) (termed AIRM2; sequence
data available from EMBL under accession no. AJ130711;
manuscript in preparation). The 0.7-kb amplified product
contains two cDNA fragments that are both carrying an
early stop codon at position 146 (EMBL accession nos.
AJ130712 and AJ130713).
Consistent with the structural similarity between p75/
AIRM1 and other sialoadhesins, p75/ARM1 was also
found to bind RBCs. This binding was specifically inhib-
ited by Z176 mAb as well as by the neuraminidase treat-
ment of RBCs. These data suggest that p75/AIRM1 may
function as a receptor which recognizes its putative li-
gand(s) in a sialic acid–dependent manner. Carbohydrate-
binding proteins are known to play a role in a wide variety
of biological processes involving specific cell–cell interac-
tions. As suggested for CD22 (41), it is possible that sialic
acids may be required for correct orientation and presenta-
tion of the epitope (on the ligand) recognized by p75/
AIRM1.
Cross-linking of p75/AIRM1 in human NK cells deliv-
ers an inhibitory signal resulting in downregulation of
spontaneous NK cell–mediated cytotoxicity. An inhibitory
effect could also be detected on the NK cell triggering me-
diated by activating receptors such as CD16, NKp46, and
NKp44 (not shown). Coherent with its ability to mediate
inhibition, the cytoplasmic tail of p75/AIRM1 was found
to contain an ITIM that recruited the SHP-1 phosphatase
upon tyrosine phosphorylation. This, in turn, is likely to
Figure 8. Binding of AIRM1-transfected COS-7 cells to human
RBCs. COS-7 cells either mock transfected or transfected with the
VR1012–AIRM1 construct were analyzed for their ability to form ro-
settes with human RBCs. AIRM1/COS-7 binding to RBCs was also an-
alyzed in the presence of Z176 mAb or an isotype-matched mAb (anti–
p58-2) or against neuraminidase-treated (Neuram.) RBCs. A positive
rosette was defined as a COS-7 cell that bound at least seven RBCs. The
COS-7/RBC ratio used in these experiments was 1:20.
Figure 7. Chromosomal localization of p75/AIRM1 gene. A Southern
blot containing genomic DNA derived from a panel of human/hamster
somatic cell hybrids and genomic DNA from human, hamster, and mouse
tissue as controls was hybridized with the 1.2-kb p75/AIRM1 probe.
The hybrid cell lines containing chromosome (Chrom.) 19 are indicated
on the top. The positions of the 23.1-, 9.4-, 6.6-, 2.3, and 2.0-kb weight
markers are indicated on the right.800 Cloning of a Novel Sialoadhesin Member Expressed by NK Cells
inhibit downstream molecular events that are critical for
the induction of NK cell–mediated cytotoxicity. One may
ask the meaning of the inhibitory effect of p75/AIRM1 in
NK-mediated function, and what could be the functional
relationship with KIRs. KIRs appear to play a predominant
role in the discrimination between HLA class I1 cells and
cells that do not express sufficient amounts of HLA class I,
such as tumor- or virus-infected cells. Since p75/AIRM1
does not appear to recognize HLA class I molecules, it is
possible to speculate that this receptor may play a role in
recognition of still undefined sialylated proteins, possibly
present in normal cells that physiologically express low
amounts of HLA class I molecules. The expression of
ligand(s) for p75/AIRM1 may protect these cells from the
NK-mediated attack. It is evident that the identification of
the p75/AIRM1 ligand(s) will greatly help to clarify this is-
sue. In addition, it is possible that p75/AIRM1 may func-
tion during stages of NK cell differentiation from immature
precursors in which cells have acquired cytolytic potential
but have not yet expressed HLA class I–specific inhibitory
receptors. Indeed, cells with these phenotypic characteris-
tics have recently been identified in our laboratory (our un-
published data).
In conclusion, we have identified, characterized, and
cloned a novel inhibitory receptor primarily confined to
human NK cells which may play a role complementary to
that of KIRs in the regulation of NK cell function.
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